ATS 2018 International Conference

Contribution of Asthma Control Test (ACT) Total Score ≥20 or Improvement from Baseline ≥3 to the Composite Primary Effectiveness Endpoint in the Salford Lung Study in Asthma (SLS Asthma) [Board No. P880]

Location: Board no. P880

Session Type: Thematic Poster Session

Sunday

May

11:15 AM

1:00 PM

Speaker(s)/Author(s)

Loretta Jacques

BSc, PhD
GlaxoSmithKline;GSK

Neil Barnes

MD
GSK

Ashley A. Woodcock

MD
Manchester Academic Health Sciences Centre, The University of Manchester and Manchester University N;Manchester Academic Health Sciences Centre, University of Manchester and Manchester University NHS

John P. New

MB, BS, FRCP
Salford Royal NHS Foundation Trust and NorthWest EHealth;Salford Royal NHS Foundation Trust, Salford and NorthWest EHealth

Joanne Fletcher

PhD
GSK

Henrik Svedsater

PhD
GSK

Lucy Frith

MSc
GSK

Nawar Diar Bakerly

MD, FRCP
Salford Royal NHS Foundation Trust & Manchester Academic Health Sciences Centre, The University of M

Susan D. Collier

BSc, MBchB
GlaxoSmithKline;GSK

Jorgen Vestbo

MD, PhD
Manchester Academic Health Sciences Centre, The University of Manchester and Manchester University N;Manchester Academic Health Sciences Centre, The University of Manchester and University Hospital So

View Abstract

Contribution of Asthma Control Test (ACT) Total Score ≥20 or Improvement from Baseline ≥3 to the Composite Primary Effectiveness Endpoint in the Salford Lung Study in Asthma (SLS Asthma)

Parent Sessions

A34 - ASTHMA CLINICAL STUDIES I
05-20-2018 9:15 AM - 4:15 PM

Event